Open access
Aug 2026
Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus.
OBJECTIVES The objective of this paper is to evaluate pharmacodynamic changes in immune-related pathways and serological biomarkers mediated by tyrosine kinase 2 (TYK2) inhibition in patients with systemic lupus erythematosus (SLE) treated with deucravacitinib, an oral, selective TYK2 inhibitor, in the phase 2 PAISLEY...
J. Kahlenberg, Chun Wu, E. Vital et al.
· Annals of the Rheumatic Dise... · 0 citations